Fremont, CA -- October 14, 2003 -- PerkinElmer Optoelectronics, a global technology leader providing market-driven integrated solutions for biomedical and industrial applications, today announced that it has begun shipment of a custom OEM spectrophotometer platform to a global manufacturer and distributor of life science research and clinical diagnostics products.

Under the agreement, valued at $1.5 million annually with an expected life of at least five years, PerkinElmer will provide a customized, fully tested, and calibrated spectrophotometer solution. Utilizing its expertise in spectrometer engines, light sources, light management, signal processing and detection, and optics design, PerkinElmer is well positioned to deliver this newly designed product as a “plug and play” and easily integrated subsystem. The platform will be used in various life science applications - including quantification of PCR (polymerase chain reaction) products and DNA for cloning and sequencing, protein assays, monitoring cell culture growth, and spectral analysis.

PerkinElmer was selected for its ability to meet product specifications, its superior product performance, and its ability to expedite time to market by complementing critical engineering resources of the OEM partner.

“Customers depend on PerkinElmer’s unique ability to design and manufacture precision electro-optical OEM subsystems. Our solutions play a critical role in functional genomics, proteomics, cellomics, clinical diagnostics, and molecular identification,” said John Murphy, president, PerkinElmer Optoelectronics. “This contract further demonstrates our commitment to servicing the demanding OEM market for innovative life science equipment.”

PerkinElmer's spectrophotometer platforms are rugged, high performance devices that can be customized for use in analytical chemistry, clinical diagnostics, chromatography, and process monitoring, among other applications. The robust, thermally stable designs utilize high performance optics to minimize stray light and maximize optical performance. The modules include an integrated, miniature UV/Vis or NIR light source that provides extremely stable, high-intensity broadband output to ensure maximum signal to noise ratio, and also feature compact size, high speed, solid state design and RS232/USB interfaces.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) fluctuations in the global economic and political environments; (4) markets into which we sell our products decline or do not grow as anticipated; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) our ability to produce an adequate quantity of products to meet our customers' demands; (12) the manufacture and sale of products may expose us to product liability claims; (13) our failure to maintain compliance with applicable government regulations; (14) regulatory changes; (15) our failure to comply with health care industry regulations; (16) economic, political and other risks associated with foreign operations; (17) our ability to retain key personnel; (18) restrictions in our credit agreements; (19) our ability to realize the full value of our intangible assets; (20) significant fluctuations in our stock price; and (21) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2 billion in 2008, has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

		For Further Information:
		Media Contact: Kristen Kmetetz Porter Novelli Life Sciences 617.897.8272 (office) Kristen.kmetetz@porternovelli.com or Francine S. Bernitz Marketing Director, Illumination and Detection Solutions PerkinElmer, Inc. Francine.bernitz@perkinelmer.com 978.224.4321 (office) 781.789.3178 (cell)